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Abstract
Objectives—To describe first dose and steady state antiretroviral drug exposure in the female
genital tract.
Design—Non-blinded, single center, open-label pharmacokinetic study in HIV-infected women.
Method—Twenty-seven women initiating combination antiretroviral therapy underwent
comprehensive blood plasma and cervicovaginal fluid sampling for drug concentrations during the
first dose of antiretroviral therapy and at steady-state. Drug concentrations were measured by
validated HPLC/UV or HPLC-MS/MS methods. Pharmacokinetic parameters were estimated for 11
drugs by non-compartmental analysis. Descriptive statistics and 95% confidence intervals were
generated using Intercooled STATA Release 8.0 (Stata Corporation, College Station, Texas, USA).
Results—For all antiretroviral drugs, genital tract concentrations were detected rapidly after the
first dose. Drugs were stratified according to the genital tract concentrations achieved relative to
blood plasma. Median rank order of highest to lowest genital tract concentrations relative to blood
plasma at steady state were: lamivudine (concentrations achieved were 411% greater than blood
plasma), emtricitabine (395%), zidovudine (235%) tenofovir (75%), ritonavir (26%), didanosine
(21%), atazanavir (18%), lopinavir (8%), abacavir (8%), stavudine (5%), and efavirenz (0.4%).
Conclusions—This is the first study to comprehensively evaluate antiretroviral drug exposure in
the female genital tract. These findings support the use of lamivudine, zidovudine, tenofovir and
emtricitabine as excellent pre-exposure/post-exposure prophylaxis (PrEP/PEP) candidates.
Atazanavir and lopinavir might be useful agents for these applications due to favorable therapeutic
indices, despite lower genital tract concentrations. Agents such as stavudine, abacavir, and efavirenz
that achieve genital tract exposures less than 10% of blood plasma are less attractive PrEP/PEP
candidates.
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Introduction
Approximately 50% of adults living with HIV/AIDS are women [1]. Heterosexual HIV
transmission is the most prominent mode of transmission in the developing world [2]. In Africa,
where women account for an estimated 76% of HIV-infected persons aged 15–24 years [2],
alternative methods to prevent sexual transmission are urgently needed. The oral administration
of antiretroviral drugs to block HIV transmission is an attractive, minimally invasive approach
to prevention [3]. This concept is already in practice domestically, as evidenced in the published
United States guidelines for use in non-occupational post-exposure prophylaxis (nPEP) [4].
The increasing availability and use of generic antiretroviral drugs to treat HIV internationally
would allow for the use of antiretroviral drugs for the prevention of HIV transmission in
developing countries.
Early treatment with an effective antiretroviral drug regimen is most critical to preventing
successful HIV transmission, as demonstrated by experience with nPEP and experimental
animal models [5–10]. Employing antiretroviral drugs that concentrate quickly at the site of
inoculation [i.e. genital tract (GT)] for pre-exposure prophylaxis (PrEP) and post-exposure
prophylaxis (PEP) is a logical extension of this evidence. Therefore, we hypothesize that to
prevent sexual transmission of HIV in women, oral antiretroviral drugs that achieve high
concentrations quickly in the GT after a first dose would be optimal candidates for PEP or
PrEP regimens. No human pharmacology data have, however, been generated in either healthy
volunteers or HIV-infected cohorts that allow rational selection of drugs used for this purpose.
To this end, we comprehensively evaluated antiretroviral drug exposure in the female GTof
HIV-infected women for 11 commonly used antiretroviral medications in the three drug
classes: nucleoside/tide analogue reverse transcriptase inhibitors (NRTI), non-nucleoside
reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI).
Methods
Study design and population
HIV-infected, non-pregnant adult women were enrolled in a non-blinded, observational, open-
label prospective, pharmacokinetic study to assess first dose and steady-state antiretroviral
drug exposure in cervicovaginal fluid (CVF) relative to blood plasma (BP) from November
2002 to May 2006. Subjects were recruited from the Infectious Diseases Clinic at the University
of North Carolina at Chapel Hill. Exclusion criteria included the following: ≤ 17 years of age;
active bacterial, fungal, or opportunistic GT or systemic infection at the time of enrollment;
hysterectomy; pregnancy; hematocrit less than 30%; unable to abstain from sexual intercourse
or douching for 48 h prior to study visits; unable to complete a dosing card; and an estimated
drug adherence rate of <80%, as determined by dosing card and patient self-report.
The antiretroviral drug regimen was selected by the patient’s primary HIV provider. Women
could be antiretroviral naive and initiating antiretroviral drugs, changing a failing regimen, or
re-initiating antiretroviral drugs after a therapy interruption. All patients gave informed consent
prior to study participation. This protocol was approved by the Biomedical Institutional Review
Board of the University of North Carolina at Chapel Hill.
Dumond et al. Page 2













Before being enrolled into the study, patients underwent a routine pelvic examination, physical
examination, extensive sexually transmitted infection (STI) screening, and routine safety
laboratory tests, including a complete blood count, serum chemistries, liver function tests, and
serum pregnancy testing. STI screening included testing for chlamydia and gonorrhea by
cervical polymerase chain reaction (PCR), testing for trichomonas by urine culture and PCR
[11], and testing for syphilis by serum rapid plasma reagin (RPR) with confirmatory treponemal
testing if positive. STI testing was performed in the University of North Carolina Sexually
Transmitted Diseases Cooperative Research Center Microbiology Core Lab or the McLendon
Laboratories of the UNC Hospitals. Any patient with a STI at screening was referred to her
primary provider for treatment, and then offered re-screening after successfully completing
STI therapy.
Study visits
Following acceptable screening results, patients were admitted for an overnight stay in the
Verne S. Caviness General Clinical Research Center. The first dose of the new antiretroviral
drug regimen was observed, and six paired BP and CVF samples were obtained (‘first dose’
conditions). At least 3 weeks later, after continuing the regimen (‘steady-state’ conditions),
patients returned to the research center whereby the first-dose BP and CVF sampling strategy
was repeated after an observed dose. Patients were also followed monthly for an additional 6
months, with BP and GT samples obtained at a single time points 2 to 24 h postdose.
Sample collection and processing
Under both first dose and steady-state conditions, CVF and BP samples were obtained at 0
(immediately predose), 2, 4, 6, 12, and 24 h after observed doses of the antiretroviral drug
regimen. All CVF samples were obtained via direct aspiration with a volumetric aspiration
device. Subjects were instructed to remain supine for approximately 10 min prior to collection
in order to pool CVF in the posterior fornix of the vagina for optimal collection volume.
Samples at 0 and 24 h were obtained during a pelvic examination, and the remaining samples
at 2, 4, 6, and 12 h post-dose were self-collected. CVF volumes typically ranged from 0.1 to
0.4 ml per sample. A previously conducted pilot study [12] demonstrated this method to be a
reproducible and robust approach to specimen collection. To minimize any HIV RNA and drug
concentration variability, all visits were scheduled in the 7 to 10 days following the end of
menses.
After collection, directly aspirated CVF was transferred to labeled cryovials and stored at −80°
C until analysis. Whole blood was obtained using K3EDTA-containing collection tubes
(Becton Dickinson Diagnostics, Franklin Lakes, New Jersey, USA) and centrifuged at 1300
g (2600 rpm) at 4°C for 15 min. The resulting plasma was aliquoted into labeled cryovials and
stored at −80°C until analysis. Drug concentrations in BP were measured using validated high
performance liquid chromatography (HPLC)/UV methods [13–15], and concentrations in CVF
were quantified using a validated HPLC-mass spectrometry (MS)/MS method [16].
Briefly, CVF concentrations were measured using a simultaneous assay for 17 antiretroviral
drugs. After thawing, samples were centrifuged and the resultant supernatant underwent solid
phase extraction using BOND ELUT C-18 columns (Varian, Harbor City, California, USA)
as previously described [15]. Cimetidine (in acetate buffer, pH 5.0) was used as internal
standard, and was applied directly to the conditioned column prior to CVF introduction. A
Shimadzu solvent delivery system (Columbia, Maryland, USA) and a LEAP HTC Pal
thermostatted (6°C) autosampler (Carrboro, North Carolina, USA) connected to an Applied
Biosystems API4000 triple quandruple mass spectrometer and Turbospray ion source (Applied
Biosystems, Foster City, California, USA) with an Aquasil C18 column (Thermo-Electron,
San Jose, California, USA) was used for the analysis. Multiple reaction monitoring and
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positive-to-negative polarity switching were used. Assay sensitivity was 1 ng/ml for abacavir
(ABC); 5 ng/ml for lamivudine (3TC), zidovudine (ZDV), emtricitabine (FTC), lopinavir
(LPV), atazanavir(ATV) and efavirenz (EFV); and 10 ng/ml for tenofovir (TDF), didanosine
(ddI), stavudine (d4T) and ritonavir (RTV). Overall assay precision was 2.0–14.3 CV%, and
accuracy was 88–113%. Recovery for the drugs studied ranged from 80% for RTV and LPV
to 99% for 3TC, ddI and ABC.
All analytical work was performed by the UNC Center for AIDS Research (CFAR) Clinical
Pharmacology and Analytical Chemistry Core, which participates in quarterly national and
international external proficiency testing [17,18]. These results consistently demonstrate high
levels of accuracy and precision for our antiretroviral assays.
Data analysis methods
Pharmacokinetic parameters, including the area under the time–concentration curve
(AUC0−τ), were estimated for both CVF and BP using WinNonlin (version 4.0.1, Pharsight,
Inc. Mountain View, California, USA). For these computations, concentration measurements
below the lower limit of detection were imputed as zero and those below the lower limit of
quantitation (LLQ) were imputed as ½ LLQ. For each antiretroviral agent, the GT: BP
AUC0−τ ratios were calculated, and multiplied by 100 to represent penetration of drug into the
GT relative to BP [19]. Descriptive statistical methods, particularly medians and the
interquartile range (IQR), were used in the primary analyses of these AUC ratios. The 95%
confidence intervals of the median AUC ratios for each drug at each visit were calculated using
Intercooled STATA Release 8.0 (Stata Corporation, College Station, Texas, USA).
Results
Demographics
Demographic data for the 27 women enrolled are presented in Table 1. The study population
was predominantly African American (70%), middle-aged (median: 35 years; IQR: 31–42
years), with a BP HIV RNA of 4.7 (IQR, 4.0–5.0) log10 copies/ml and a CD4+T-cell count of
307 (220–372) cells/μl at study entry. As most subjects were antiretroviral experienced (67%),
the provider-selected regimens varied widely. Seventy percent (19/27) of the regimens
contained 3TC. TDF was found in 56% of the regimens, ABC in 30%, and ZDV in 24%. Thirty-
three percent of the women were on EFV-containing therapy, and 52% were on a PI-containing
regimen (57% ATV/r, 36% LPV/r, and 7% ATV); one woman (4%) received EFV with LPV/
r. Two individuals (7%) were on triple nucleoside therapy, and one (4%) received nevirapine.
(Nevirapine data not presented.)
Antiretroviral pharmacokinetics in blood plasma and genital tract
Using the direct cervicovaginal aspirate sampling method, all drugs were detected in the GT
2–4 h after the first dose, and reached peak concentrations for the dosing interval by 4–6 h.
Figure 1a–g depict individual pharmacokinetic profiles of selected antiretroviral drugs over
their respective dosing intervals in BP and GTafter a first dose and at steady state. These drugs
were selected as achieving the highest concentrations in their respective drug classes, using
doses and/or dosing regimens most commonly prescribed.
Nucleoside/tide reverse transcriptase inhibitors
Figure 1a depicts extracellular ZDV concentrations over a 12 h dosing interval. After a first
dose, ZDV concentrations were detectable in both BP and GT secretions 2 h after a dose.
Although BP concentrations steadily declined from that time point, GT concentrations
continued to increase and reached a maximum concentration at 6 h post-dose. At steady state,
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concentrations were detectable in the GT, but not in BP, prior to dosing. The GTand BP
concentrations were similar 4 h postdose; after this point, GT concentrations declined
minimally, while BP concentrations declined significantly. An average extracellular BP
concentration (Cav) previously suggested for efficacy [20,21], is indicated in the figure as a
black horizontal line. GT concentrations were at or near this target for a longer period of time
than BP concentrations.
Lamivudine exposure after once-daily dosing can be seen in Fig. 1b. Similar results were seen
for subjects receiving twice daily dosing (not shown). GT concentrations were approximately
1-log higher than BP concentrations throughout the dosing interval after a single dose and
under steady-state conditions. The GT concentrations exceeded the suggested average
extracellular target concentration (Cav) previously suggested for efficacy [20,21]. Similarly,
GT concentrations of FTC were higher than BP concentrations from 6–24 h after a single dose,
and remained higher than BP concentrations during the entire dosing interval under steady-
state conditions (Fig. 1c). For TDF (Fig. 1d), the GT concentrations were at or above BP
concentrations 4 h after a dose, and remained higher throughout the dosing interval.
Protease inhibitors
Pharmacokinetic profiles for ATV and LPV are shown in Fig. 1e and f. In contrast to the NRTIs,
ATV GT concentrations (when given as 300 mg ATV/100 mg RTV once daily) were lower
than BP throughout the dosing interval both after first dose and at steady-state. These
concentrations still, however, exceeded a suggested BP trough concentration of 150 ng/ml for
efficacy against wild-type virus [22]: the mean (±SD) ATV trough concentration in the GT
after a first dose was 417 ± 818 ng/ml, and at steady state was 169 ± 148 ng/ml. The GT
concentrations for LPV were also lower than BP at both first dose and steady-state. A suggested
LPV trough concentration for efficacy of 1000 ng/ml is depicted in Fig. 1f [22]. The GT
concentrations approached this target over a dosing interval, and briefly exceed this
concentration at the 4-h time point (mean ± SD = 1522 ± 1659 ng/ml). At the end of the dosing
interval, mean ±SD GT concentrations were 437 ± 631 ng/ml after a single dose and 354 ± 384
ng/ml at steady-state.
Nonnucleoside reverse transcriptase inhibitors
The summary EFV pharmacokinetic profiles are shown in Fig. 1g. The BP and GTexposures
are clearly distinct. Whereas EFV was detected in the GT 2 h after a single dose, concentrations
were approximately 10 ng/ml: 2 logs lower than BP. The suggested target trough concentration
for EFV is 1000 ng/ml [22].
Pharmacokinetic parameters
Table 2 lists steady-state pharmacokinetic parameter estimates in BP and GT for each drug.
BP concentrations at the end of the dosing interval (Cτ) and the AUC over 24 h (AUC0–24h)
for each drug were within the expected range. On average, GT time to maximal concentration
(Tmax) was delayed in comparison with BP. All drugs were, however, detectable in GT
secretions within 4 h of antiretroviral drug ingestion.
Table 3 lists median (IQR) GT: BP AUC ratios in rank order from the highest exposure to
lowest exposure after single and multiple doses of antiretroviral drugs. A ratio equal to 100%
indicates drug exposure in the GT that is equivalent to BP. Therefore, ratios greater than 100%
indicate greater GT drug exposures than BP, and those less than 100% indicate lower GT
exposures than BP.
ZDV, 3TC, and FTC achieved greater GTexposures than BP both after a single dose and under
steady-state conditions. The median GT exposures for these drugs ranged from 111 to 371%
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that of BP after a single dose and 235 to 411% after multiple doses. TDF GT exposure at first
dose achieved a median of 135%, and 75% of BP at steady state. In contrast, ATV, stavudine
(d4T), EFV, and RTVachieved lower GTexposures than BP, ranging from 0.5 to 21% that of
BP after a first dose, and 0.4 to 26% after multiple doses.
Discussion
This is the first study to comprehensively evaluate antiretroviral drug exposure in the GT after
single and multiple dosing. In this study of 27 HIV-infected women, GT concentrations of all
11 antiretroviral drugs reported here were detected rapidly after single doses. Differing
GTexposures between the drugs relative to BP, however, suggest that only certain drugs may
be preferable for PrEP or PEP regimens.
Of the nucleoside analogs evaluated, 3TC, ZDV, FTC, and TDF achieved GT concentrations
similar to, or higher than, BP, and therefore would be excellent PEP and PrEP candidates for
further study. Mean 3TC and ZDV concentrations in the GT were near or above extracellular
concentrations suggested for clinical efficacy [20,21]. The median GT AUC of FTC at steady
state was approximately three times higher than the suggested BP AUC of 10 ug*h/ml for
clinical efficacy [23].
Of the other compounds studied, LPVand ATVachieved low to moderate GT concentrations.
Since these may be similar to the recommended BP trough concentrations necessary for
efficacy in patients with wild-type HIV-1 virus [22], further study of these agents is warranted
for use in PrEP and PEP either given alone or in combination with NRTIs. EFV had very low
GT concentrations relative to BP, and is unlikely to be useful in PEP/PrEP regimens.
Low drug exposures in the GT may contribute to higher viral shedding in the GT and the
development of viral resistance. Recently, receipt of NNRTI-containing therapy was found to
be independently associated with HIV shedding at the cervix (odds ratio = 2.24 compared to
a PI-based regimen) in 107 women (31 on NVP and 76 on EFV) [24]. Additionally, data
presented from the ACTG study A5077 suggested an increased rate of NNRTI mutations in
the female GT [25] in individuals who were highly antiretroviral drug-experienced.
Additionally, a recent study of 14 women found three with partial or complete
compartmentalization of HIV in the GT compared to BP [26]. In our study, the low exposures
of EFV (0.5% GT: BP AUC) observed in this study suggest NNRTI drug resistance to be
biologically plausible [27,28]. As drug concentrations in the GT are seldom measured,
however, a direct relationship between drug exposure, viral burden, and viral resistance
patterns in the GT has not been established.
It is currently unclear which specific mechanisms and physicochemical properties of drugs
dictate passage into the female GT. However, drug penetration appears to be related to the
protein-binding capacity of each drug. Highly protein-bound drugs such as LPV (98–99%
protein bound) [29] and ATV (86% protein bound) [30] had lower GT exposures (8 and 18%,
respectively, at steady state), whereas drugs with low protein-binding such as the nucleoside/
tide analogs ZDV, 3TC, and FTC (<4% to <38% protein bound) [31–33], generally had higher
GTexposures (ranging from 235–411%). d4Tand ddI were exceptions to this trend, as GT
exposures were low (5 and 21%, respectively) despite <5% protein binding [34,35]. For d4T,
peak plasma concentrations occur at approximately 2 h post-dose. Since our first sampling time
was 2 h post-dose, it is possible that the true peak concentration was not captured, and complete
exposure information was not obtained.
To further this initial pharmacokinetic evaluation, a number of investigations are desirable.
Linking drug exposure to biologic response (e.g., decrease in HIV RNA) in the female GT is
critical to confirm that higher extracellular drug concentrations are predictive of a more potent
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response and guide drug selection for PrEP and PEP. Pharmacokinetic/pharmacodynamic
modeling analyses are ongoing in our laboratory to evaluate the correlation between differential
GT drug exposure and virologic response. Additionally, our previous NRTI work in male GT
mononuclear cells suggests similar or lower concentrations of intracellular triphosphate active
metabolites compared to BP despite higher GT extracellular drug exposures [36]. Therefore,
research characterizing the intracellular active triphosphorylated metabolites for NRTIs in the
female GT is necessary. Our study observed an extracellular half-life of TDF in the GT
secretions twice as long as the extracellular half-life of TDF in BP, suggesting that TDF might
be dosed at extended intervals for PEP or PrEP. Under first dose conditions, the median half-
life was 14.5 h (95% CI: 3.6–29.2 h) in the GT, and 7.4 h (95% CI: 4.8–12.4 h) in BP (data
not shown). However, characterizing intracellular concentrations of tenofovir diphosphate in
GT mononuclear cells would be most important to move this application forward.
Although for most drugs, no differences in plasma drug exposure have been found between
HIV-infected subjects and healthy volunteers [28–32], it may also be beneficial to evaluate the
GT exposures of these drugs in healthy women, as they will be the primary recipients of PrEP
and PEP. Additionally, no data exist on the influence of local infection and inflammation on
drug concentrations in the female GT. As 130–1800% increases in drug concentrations have
been documented with the inflammation present in meningitis and prostatitis, [37–39], GT
infections may also increase antiretroviral drug concentrations in addition to increasing
susceptibility to HIV infection [40–42].
Finally, understanding antiretroviral protein binding in the GT is necessary. This investigation
measured total (protein unbound drug + protein bound drug) drug concentrations in both BP
and GT. However, it has been suggested that concentrations of drug binding proteins
(specifically albumin and alpha-1 acid glycoprotein) in the female GT may be lower than in
BP [43]. If this is true, despite differences in total drug concentrations between BP and GT,
free drug concentrations in the GT may be similar to, or greater than, BP. Hence, free drug
concentrations may be a more important predictor of efficacy. Although these types of
investigations are technically difficult and lend themselves better to in-vitro study, this work
will be required for a more thorough understanding of antiretroviral behavior in the GT.
In conclusion, this investigation is the first to comprehensively evaluate antiretroviral drug
exposure in the female GT. Regardless of drug, GT concentrations were detected 2–4 h after
a single antiretroviral dose. Additionally, GT exposures were similar after a first dose and at
steady state. The results of this investigation support the use of 3TC, ZDV, TDF, and potentially
FTC as excellent PrEP/PEP candidates. ATVand LPV/r may prove useful agents due to
favorable GT concentrations in relation to HIV-1 wild-type susceptibility. We believe agents
that achieve less than 10% of BP exposure, such as EFV and d4T, are less likely PrEP/PEP
candidates.
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(a) Mean (SE) pharmacokinetic profile of zidovudine (ZDV) over a 12 h dosing interval in
blood plasma (BP) and genital tract (GT) at first dose and steady state. Subjects received 300
mg every 12 h. The solid line represents an extracellular target concentration previously
suggested as efficacious in clinical studies [20,21]. (b) Mean (SE) pharmacokinetic profile of
lamivudine (3TC) over a 24 h dosing interval in BP and GT at first dose and steady state.
Subjects received 300 mg every 24 h. The solid line represents an extracellular target
concentration previously suggested as efficacious in clinical studies [20,21]. (c) Mean (SE)
pharmacokinetic profile of emtricitabine (FTC) over a 24 h dosing interval in BP and GT at
first dose and steady state. Subjects received 200 mg every 24 h. No target concentration for
clinical efficacy has been defined. (d) Mean (SE) pharmacokinetic profiles of tenofovir (TDF)
over a 24 h dosing interval in BP and GT at first dose and steady state. Patients received 300
mg of TDF every 24 h. No target concentration for clinical efficacy has been defined. (e) Mean
(SE) pharmacokinetic profile of atazanavir (ATV) over a 24 h dosing interval in BP and GT
at first dose and steady state. Patient received 300 mg of ATV and 100 mg of ritonavir (RTV)
every 24 h. The solid line represents the suggested clinical target concentration for ATV [22].
(f) Mean (SE) pharmacokinetic profile of lopinavir (LPV) over a 12 h dosing interval in BP
and GT at first dose and steady state. Subjects received 400 mg of LPV and 100 mg of RTV
every 12 h. The solid line represents a suggested clinical target concentration for LPV [22].
(g) Mean (SE) pharmacokinetic profile of efavirenz (EFV) over a 24 h dosing interval in BP
and GT at first dose and steady state. Subjects received 600 mg of EFV every 24 h. The solid
line represents a suggested clinical target concentration for EFV [22].
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Table 1
Baseline demographics and antiretroviral regimen components of 27 study women.
Age (years) 35 (31–42)
Race/ethnicity
 African American 19 (70%)
 Caucasian 5 (19%)
 Hispanic 2 (7%)
 American Indian 1 (4%)
 Antiretroviral-experienced 18 (67%)
 Baseline HIV RNA (log10 copies/ml) 4.7 (4.0–5.0)
Baseline CD4+ T cells (cells/μl) 307 (220–372)








NNRTI components of antiretroviral regimens
 EFV 9 (33%)
 NVP 1 (4%)





 Triple NRTI 2 (7%)
 EFV/LPV/r 1 (4%)
Data presented as median (interquartile range) or number (percentage). ABC, abacavir; ATV, atazanavir; ATV/r, atazanavir/ritonavir; ddI, didanosine;
d4T, stavudine; EFV, efavirenz; FTC, emtricitabine; LPV/r, lopinavir/ritonavir; NNRTI, non- nucleoside reverse transcriptase inhibitor; NRTI,
nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; TDF, tenofovir; ZDV, zidovudine; 3TC, lamivudine.
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